Novel targeted therapies for eosinophilic disorders

J Allergy Clin Immunol. 2012 Sep;130(3):563-71. doi: 10.1016/j.jaci.2012.07.027.


Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders.

Publication types

  • Review

MeSH terms

  • Alefacept
  • Alemtuzumab
  • Antibodies, Anti-Idiotypic / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Cell Movement / drug effects
  • Clinical Trials as Topic
  • Eosinophils / physiology*
  • Humans
  • Hypereosinophilic Syndrome / drug therapy*
  • Interleukin-5 / antagonists & inhibitors
  • Omalizumab
  • Phosphorothioate Oligonucleotides / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use


  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal, Humanized
  • Interleukin-5
  • Phosphorothioate Oligonucleotides
  • Recombinant Fusion Proteins
  • TPI ASM8
  • Omalizumab
  • reslizumab
  • Alemtuzumab
  • benralizumab
  • mepolizumab
  • Alefacept